Mesoblast Limited (ASX:MSB) Insider Acquires A$506,207.31 in Stock

Mesoblast Limited (ASX:MSB) insider Eric Rose acquired 30,310 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was acquired at an average price of A$16.70 ($10.57) per share, with a total value of A$506,207.31 ($320,384.37).

Mesoblast Stock Performance

The company has a debt-to-equity ratio of 24.76, a current ratio of 1.18 and a quick ratio of 1.82.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.